TERN · CIK 0001831363 · operating
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing small-molecule therapeutic candidates focused on oncology and metabolic diseases. The company's pipeline includes TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1 trials for chronic myeloid leukemia; TERN-501, a thyroid hormone receptor beta agonist in Phase IIa development for metabolic dysfunction-associated steatohepatitis (MASH); and oral formulations of TERN-601, a glucagon-like peptide-1 receptor agonist, along with the TERN-800 series of glucose-dependent insulinotropic polypeptide receptor modulators, both targeting obesity treatment.
The company operates as a clinical-stage entity with no approved products generating commercial revenue. As of the available data, Terns maintains a lean operational structure with 59 full-time employees and is headquartered in Foster City, California. The company was incorporated in Delaware in 2016 and trades on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.12 | $-1.12 | +11.8% | |
| 2023 | $-1.27 | $-1.27 | +24.0% | |
| 2022 | $-1.67 | $-1.67 | — | |
| 2021 | — | — | — |